» Articles » PMID: 2102029

[Effectiveness and Tolerance of Long-term Uricosuric Treatment]

Overview
Specialty General Medicine
Date 1990 Dec 1
PMID 2102029
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In an open-controlled, randomized trial over 24 weeks, the serum uric acid lowering effect of a daily dose of 100 mg allopurinol in combination with 20 mg benzbromarone compared to 300 mg allopurinol only was investigated on a total of 60 patients suffering from hyperuricemia. Both preparations led to a decrease of the serum uric acid value to normal. In those patients however, who had received the combination the reduction of the serum uric acid level was more pronounced. Tolerance was generally good. Side-effects were not reported.

Citing Articles

Uricosuric medications for chronic gout.

Kydd A, Seth R, Buchbinder R, Edwards C, Bombardier C Cochrane Database Syst Rev. 2014; (11):CD010457.

PMID: 25392987 PMC: 11262558. DOI: 10.1002/14651858.CD010457.pub2.


Allopurinol for chronic gout.

Seth R, Kydd A, Buchbinder R, Bombardier C, Edwards C Cochrane Database Syst Rev. 2014; (10):CD006077.

PMID: 25314636 PMC: 8915170. DOI: 10.1002/14651858.CD006077.pub3.


A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?.

Lee M, Graham G, Williams K, Day R Drug Saf. 2008; 31(8):643-65.

PMID: 18636784 DOI: 10.2165/00002018-200831080-00002.


Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Day R, Graham G, Hicks M, McLachlan A, Stocker S, Williams K Clin Pharmacokinet. 2007; 46(8):623-44.

PMID: 17655371 DOI: 10.2165/00003088-200746080-00001.